FDA Approves Merck ’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence

Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved ZINPLAVA ™ (bezlotoxumab) Injection 25 mg/mL. Merck anticipates
making ZINPLAVA available in first quarter 2017.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more

Source: Merck.com - Corporate News - October 22, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK CDI MSD ZINPLAVA Source Type: news